Nothing to be nervous about, I think everyone can see this stock isn't going anywhere but down. How far down? I think the days over 2 are very limited.
My guess is that Watson had the foresight to update their data when the new bioequivalence standards came out and filed a supplement to their ANDA. You would think that Par would have checked with the FDA at that time to see if they were subject to the new standards and gotten written confirmation either way. Par obviously dropped the ball and it has cost IPCI big time.
News 
Market Data 
Discover 
AI
